Immune Checkpoint Inhibitor-related Adverse Events

SITC's Cancer Immunotherapy Guidelines program is a
collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as  well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.

The Immune Checkpoint Inhibitor-related Adverse Events Guideline Expert Panel was formed to generate consensus recommendations pertaining to the treatment of patients with Immune checkpoint inhibitors (ICIs). ICIs are antibodies designed to block key regulatory signals that dampen immune responses, counteracting immune suppression in the tumor microenvironment and thus enabling tumor-reactive T cells to mount a more effective anti-cancer response. While ICIs have improved patient outcomes in a number of clinical settings, the same mechanisms that underpin their effective anti-tumor properties may cause unique toxicities, specifically immune-related adverse events (irAEs). As ICIs increasingly become integrated into treatment plans for an ever-increasing number of disease settings, there is a need for clear, expert guidance on the recognition and management of irAEs. SITC assembled the expert panel to discuss and is currently generating recommendations on best practices for addressing some of the most commonly reported irAEs that arise during treatment with ICIs, including gastrointestinal, musculoskeletal, and dermatologic toxicities, among other key considerations for oncologists treating their patients with these agents. A companion guideline on the management of immune effector cell-related adverse events published on December 16, 2020 in the Journal for ImmunoTherapy of Cancer (JITC)

SITC Call for Comment

The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines Immune Checkpoint Inhibitor-related Adverse Events Expert Panel is pleased to invite public comment from January 19 – February 8, 2021 for the draft of the forthcoming, “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events” manuscript.

SITC’s open public comment period allows for key stakeholders and experts in the field to critically review the guideline prior to publication and provide input on the recommendations contained therein. SITC is committed to maintaining full transparency in our guideline development process, in alignment with the Institute of Medicine’s standards. The public comment period represents an opportunity to engage parties potentially affected by the guideline from both within and outside of our membership, in service of the ultimate purpose of providing a quality product to the medical community.

Instructions for Providing Comment 

• Individuals interested in reviewing and commenting on the manuscript will be required to sign a non-disclosure and confidentiality agreement prior to receiving the draft guideline recommendations. Download the form HERE and email the requested information to scientificresources@sitcancer.org.
• Once SITC has received the signed form, we will email you a copy of the guideline for your review.
• Individuals must identify themselves by name and affiliation – anonymous comments will not be considered for review.
• All comments must be received by Monday, February 8, 2021, to be considered.

All comments received during the open comment period will be reviewed by the Immune Checkpoint Inhibitor-related-Adverse Events Expert Panel leadership. Comments are advisory only and SITC will consider all submissions, but will not respond directly to individual commenters.

SITC Immune Checkpoint Inhibitor-related Adverse Events Expert Panel

Members

Hamzah Abu-Sbeih, MD — University of Missouri-Kansas City

Paolo Antonio Ascierto, MD — Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale'

Jill Brufsky, PharmaD (Patient) —  University of Pittsburgh Medical Center

Laura C. Cappelli, MD, MHS, MS — Johns Hopkins University

Frank B. Cortazar, MD —  Massachusetts General Hospital

David E. Gerber, MD — Harold C. Simmons Comprehensive Cancer Center

Lamya Hamad, RPh, MPH — Roswell Park Comprehensive Cancer Center

Eric Hansen, MD — Roswell Park Comprehensive Cancer Center

Douglas B. Johnson, MD, MSCI — Vanderbilt-Ingram Cancer Center

Mario E. Lacouture, MD — Memorial Sloan Kettering Cancer Institute

Gregory A. Masters, MD, FACP, FASCO — Helen F. Graham Cancer Center

Jarushka Naidoo, MBBCH MHS — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Beaumont Hospital, The Royal College of Surgeons of Ireland.

Michele Nanni, PA — Roswell Park Comprehensive Cancer Center

*Miguel-Angel Perales, MD — Memorial Sloan Kettering Cancer Center

Igor Puzanov, MD, MSCI, FACP — Roswell Park Comprehensive Cancer Center

Bianca D. Santomasso, MD, PhD — Memorial Sloan Kettering Cancer Center

Satish P. Shanbhag, MBBS, MPH — Johns Hopkins University

Rajeev Sharma, MBBS, MD, FACE — Roswell Park Comprehensive Cancer Center

Dimitra Skondra, MD, PhD — The University of Chicago Medical Center

Jeffery A. Sosman, MD — Northwestern University

Michelle Turner, NP — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

*SITC is a proponent for collaboration and harmonization of efforts between like-minded organizations whenever possible. SITC wishes to thank the American Society of Transplantation and Cellular Therapy (ASTCT) for providing a representative to serve on SITC’s Immune Checkpoint Inhibitor-related Adverse Events Expert Panel to aid in the development of this clinical practice guideline.